Literature DB >> 20688393

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

Richard M Stone1, Barry Moser, Ben Sanford, Philip Schulman, Jonathan E Kolitz, Steven Allen, Wendy Stock, Ilene Galinsky, Ravi Vij, Guido Marcucci, David Hurd, Richard A Larson.   

Abstract

Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20688393      PMCID： PMC3023007          DOI： 10.1016/j.leukres.2010.07.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  25 in total

1.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors:  P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

Review 2.  High dose cytarabine: a review.

Authors:  B J Bolwell; P A Cassileth; R P Gale
Journal:  Leukemia       Date:  1988-05       Impact factor: 11.528

3.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.

Authors:  Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

4.  A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

Authors:  William J Kell; Alan K Burnett; Raj Chopra; John A L Yin; Richard E Clark; Ama Rohatiner; Dominic Culligan; Ann Hunter; Archie G Prentice; Donald W Milligan
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

5.  A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Authors:  Alexander E Perl; Margaret T Kasner; Donald E Tsai; Dan T Vogl; Alison W Loren; Stephen J Schuster; David L Porter; Edward A Stadtmauer; Steven C Goldstein; Noelle V Frey; Sunita D Nasta; Elizabeth O Hexner; Jamil K Dierov; Cezary R Swider; Adam Bagg; Alan M Gewirtz; Martin Carroll; Selina M Luger
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

6.  The characteristics and outcome of patients with late relapse acute myelogenous leukemia.

Authors:  H M Kantarjian; M J Keating; R S Walters; K B McCredie; E J Freireich
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

7.  Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.

Authors:  A D Ho; T Lipp; G Ehninger; H J Illiger; P Meyer; M Freund; W Hunstein
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

Review 8.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

Authors:  Francis Giles; Elihu Estey; Susan O'Brien
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

9.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

10.  Improved survival for patients with acute myelogenous leukemia.

Authors:  A J Mitus; K B Miller; D P Schenkein; H F Ryan; S K Parsons; C Wheeler; J H Antin
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544
View more
  6 in total

1.  Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

Authors:  Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles
Journal:  Br J Haematol       Date:  2012-06-15       Impact factor: 6.998

Review 2.  What happened to anti-CD33 therapy for acute myeloid leukemia?

Authors:  Joseph G Jurcic
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

3.  New considerations in the design of clinical trials for the treatment of acute leukemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Clin Investig (Lond)       Date:  2011-04-01

Review 4.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

5.  Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.

Authors:  Yoshikazu Ito; Atsushi Wakita; Satoru Takada; Masahiro Mihara; Moritaka Gotoh; Kazuma Ohyashiki; Shigeki Ohtake; Shuichi Miyawaki; Kazunori Ohnishi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2012-09-06       Impact factor: 2.490

6.  Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Authors:  Jonathan A Webster; Raoul Tibes; Larry Morris; Amanda L Blackford; Mark Litzow; Mrinal Patnaik; Gary L Rosner; Ivana Gojo; Robert Kinders; Lihua Wang; L Austin Doyle; Catherine J Huntoon; Larry M Karnitz; Scott H Kaufmann; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-09-20       Impact factor: 3.715
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.